FlugenFluGen is a clinical stage vaccine company working to solve the urgent need for a more effective influenza vaccine with broader coverage and longer duration of action. The mechanism of its M2SR, single replication, intranasal flu vaccine mimics wildtype infection generating a robust and unique immune signature. Clinical studies to test M2SR’s ability to protect against substantially drifted strains are underway.
